Apparently, most literature is biased to the United States and it shows that prostate cancer is leading cancer among the male population in this region. The American Cancer Society shows that 217,730 new cases of prostate cancer and 32,050 subsequent deaths occurred in 2010 (Phillips & Barqawi, 2011). A common health promotion message is that early detection of cancer through early screening is paramount in timely intervention and subsequent reduction in mortality rate and improved quality of life. However, the case of prostate cancer seems to oppose this ideology; hence, the purpose of this paper is to understand preventive approaches and therapies used to manage prostate cancer. The US Preventive Services Task Force (USPSTF) gives recommendations against prostate-specific antigen (PSA) -based screening for prostate cancer. There was no association between early screening and reduced mortality rate10 years after increased efforts to encourage early screening. This recommendation to halt screening was made at the same time when UPSPSTF conclusively declared that there was a lack of adequate evidence that would form a basis for the comparison between benefits and harms of prostate cancer screening in men less than 75 years of age (Lin, Croswell, Koenig, Lam & Maltz, 2011). According to Moyer (2012), treatments for prostate cancer upon diagnosis include palliative care, active surveillance, and curative treatment in the event that the disease has a poor prognosis. In the years between 1986 and 2005, PSA-based screening led to the use of surgery and radiation therapy. Innovative techniques, for example, external beam radiotherapy, adjuvant and neoadjuvant therapies, have led to significant improvements in the curative management of prostate cancer, but their viability is yet to be determined through more credible research. Phillips & Barqawi (2011) highlight the various chemopreventive approaches used in the prevention of this cancer. Currently, evidence supports the use of 5-alpha reductase inhibitors (5-ARI) and micronutrients to act as inhibitors of this disease. Unfortunately, the use of 5-ARIs is not economically viable; hence, socioeconomic status is likely to influence the choice and use of chemoprevention agents. Ethnicity and socioeconomic status intertwine because black Americans, Africans and Asians face the challenge of cancer chemoprevention due to the high costs associated with some of the chemoprevention strategies. The use of 5-Alpha reduc-tase inhibitors and natural substances are used for both primary and secondary prevention (Phillips & Barqawi, 2011). Primary prevention entails preventing the cancer before it forms. Secondary prevention prevents the progression of premalignant lesions to cancer. Finasteride and dustasteride (5-ARI medications) are used to slow and halt prostate growth with benign prostatic hypertrophy (BPH) (Phillips & Barqawi, 2011). In the event of prostate cancer, the expression of type 1 isoenzyme is enhanced while there is no effect on isoenzyme 2 with the advent of this cancer. The 5-ARIs, which inhibit androgen receptor (activation), reduce prostatic volume by 30% in addition to reduced PSA levels of 50% to 60% (Phillips & Barqawi, 2011). The main micronutrient that has been in foc